Artiva Biotherapeutics, Inc. (ARTV)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Artiva Biotherapeutics, Inc. reported revenue of $0, down 100.0% from the prior year. The company ran a net loss. It held $130.94M in total assets against $20.97M in total liabilities.
Key ratios (FY2025)
-76.3%
Return on equity
-100.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $251.0K | $33.49M | — |
| Operating Income | -$89.81M | -$67.28M | -$30.67M | — |
| Net Income | -$83.86M | -$65.37M | -$28.72M | — |
| EPS (Diluted) | $-3.43 | $-5.81 | $-35.78 | — |
| Total Assets | $130.94M | $209.58M | $105.11M | — |
| Total Liabilities | $20.97M | $22.94M | $50.72M | — |
| Shareholders' Equity | $109.97M | $186.64M | -$162.01M | -$140.70M |
| Cash & Equivalents | $26.70M | $40.23M | $53.50M | — |
| Operating Cash Flow | -$76.75M | -$55.03M | -$47.43M | — |
| Capital Expenditures | $2.59M | $642.0K | $3.26M | — |
| Shares Outstanding | 24.44M | 11.26M | 802.7K | — |